alexa Peptidyl Derivatives Of Diaryl 1-aminoalkylphosphonates As A New Potential Antibacterial And Antiviral Agent
ISSN: 2161-0401

Organic Chemistry: Current Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd European Organic Chemistry Congress
March 02-03, 2017 Amsterdam, Netherlands

Jozef Oleksyszyn
Wrocław University of Technology, Poland
Keynote: Organic Chem Curr Res
DOI: 10.4172/2161-0401.C1.015
Abstract
Statement of the Problem: The bacterial and viral infections are still serious health risk around the world. There is a need for new antibacterial and antiviral agent development. Peptidyl derivatives of diaryl 1-aminoalkylphosphonates are potent, irreversible and selective inhibitors of serine proteases including bacterial and viral serine proteases. The activities of these enzymes are crucial for survival of bacteria and in life cycle of certain viruses. Effective inhibitors of these enzymes could be a next generation of antibacterial and antiviral agents. Methodology & Theoretical Orientation: Applying the described earlier methodologies we have design and synthesized several new inhibitors for bacterial and viral serine proteases including chymotrypsin-like serine protease from Staphylococcus aureus SplA and SplB (1, 2), endoproteinase GluC (V8 proteinase) (3), subtilisin-like protease SufA from Finegoldia magna (4), protease CtHtrA from Chlamydia trachomatis (5) and viral protease NS3/4A of hepatitis C virus and N2B/NS3 protease from west Nile virus. Conclusion & Significance: Some of these inhibitors showed excellent activity in vitro and for inhibitors of serine protease from Chlamydia trachomatis the significant activity in vivo was observed. In general more in vivo studies are required.
Biography

Józef Oleksyszyn has received his PhD (1974-1977) and DS (Doctor of Sciences, Habilitation, 1978-1986) from Faculty of Chemistry, Wrocław University of Technology, Poland. Currently, he is a Professor of Biochemistry at Wrocław University of Technology, Poland. He had two Post-doctoral Scholarship, the first (1982-1984) in the Department of Chemistry, Michigan University under Professor Arthur Ashe and the second one at Georgia Institute of Technology under Professor James C Powers. During the period of 1990-2000, he has been working in few biotechnology companies including CORTECH Inc., (Denver, CO), OsteoArthritis Inc., (Boston, MA) and DYAX (Boston, MA), in the positions from Research Scientist to the Director of Chemical Sciences. One of the compounds, inhibitor of human neutrophil elastase, designed and synthesized by him went for the clinical trial (Cortech). He discovered an amidoalkylation reaction of trivalent phosphorus derivatives, named in literature as “Oleksyszyn Reaction”. In 2002, he returned to Wrocław Technology University, where he has build-up the Division of Medicinal Chemistry and Microbiology that he has headed during the period of 2006-2011. His research resulted in more than 70 publications in reputed journals and more than 50 patents and patent applications, including 8 USA patents. He is a Member of American Chemical Society. He has been serving as the Editorial Member of several reputed journals like Anti-cancer Agents in Medicinal Chemistry, American Journal of Cancer Prevention, Journal of Pharmacological & Biomedical Analysis, Cell Biology: Research & Therapy, and has been an Expert Reviewer for several journals. His research interest includes new approaches for the anticancer therapies, enzyme inhibitors as new drugs, including new antibacterial drugs, inhibitors of proteolytic enzymes as a new drug generation.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords